Diatide Announces FDA Has Filed New Drug Application For AcuTect; Product Receives Priority Status.
Business Wire › September 08, 1997
Linked as:
Extract
Diatide Announces FDA Has Filed New Drug Application For AcuTect; Product Receives Priority Status.
LONDONDERRY, N.H.--(BW HealthWire)--Sept. 8, 1997--Diatide, Inc. (NASDAQ:DITI) announced today that the United States Food and Drug Administration (FDA) notified the Company by telephone that Diatide's New Drug Application for AcuTect(tm) (Kit for the preparation of Technet...
See the full content of this document
Sponsored links
